In search of: Researchers explore the ocean for alternatives to opioids

November 28, 2017
In search of: Researchers explore the ocean for alternatives to opioids
Credit: University of Utah Health

What does a marine snail's ability to kill prey with two shots of venom have to do with the opioid epidemic ravaging the United States?

More than you could imagine.

A multi-disciplinary team of researchers with expertise in biology, anesthesiology, pharmacology, and medicinal chemistry at U of U Health received a grant from the Department of Defense to identify new, natural compounds to develop non- drugs for . The approximately $10 million grant will be distributed over four years.

Chronic lingers, affecting the patient long after an injury has healed. With few options, patients often turn to opioids and anti-inflammatory drugs that work through a limited number of molecular pathways and require increasingly higher doses to continue the analgesic effect.

"Societal dependence on opioid drugs has created an urgent need to find alternatives to these medications to treat chronic pain," said J. Michael McIntosh, M.D., professor of psychiatry at U of U Health and contributor to this project. "This project turns to ocean organisms to identify the next generation of therapeutic pain medications."

Since antiquity, scientists have exploited plant sources for , including medications from the poppy plant (opioids) and willow bark (aspirin). Few, new natural medications have been developed in the past half century.

In this study, the researchers will isolate various compounds from the of marine organisms to evaluate their analgesic and anesthetic qualities.

More than 10,000 species of sea snails, slugs and other marine mollusks roam the ocean. These organisms lack arms, nets or teeth. Despite these deficiencies, they are effective predators, having evolved an array of venoms to numb, stun and eventually subdue prey.

Credit: University of Utah Health

The numbing properties of venom are central to this study.

Previous work by this research team identified the potential analgesic properties of the venom isolated from Conus regius, a small, predatory common to the Caribbean Sea. This project will expand on this preliminary research to explore compounds from venom isolated from a variety of different marine mollusks.

Beyond compound discovery, the team will also explore underutilized biological pathways to reduce the sensation of pain and inflammation. The aim is to identify novel drugs that have the beneficial effects of opioids, but lack the adverse actions.

"We don't want to find another that works [on the same pathways] as opioids, because it will probably have the same problems with addiction and respiratory depression, among other side effects" said Russell Teichert, Ph.D., research associate professor in the Department of Biology.

The researchers will evaluate the candidate identified in this study using three rodent models that mimic chronic pain in humans to evaluate their effectiveness for future clinical trials.

"Pain is not a disease," Teichert said. "It is an important sensory response. Our intent is not to block pain, but to block abnormal (neuropathic) pain, especially if it becomes chronic."

The potential compound identified from C. regius will be taken one step further in this larger study. The team aims to develop a stable drug that can be metabolized in the body and can elicit the , similar to opioids for .

"We really hope that we will find a drug that could be as effective for severe pain as opioids but has far less side effects and is not addictive," Teichert said.

The team is building on their previous success in which a compound was isolated from the venom of the cone snail C. magus that inhibits pain by blocking calcium channels. The isolated compound was developed into the drug Prialt, which was approved by the FDA in 2004 to treat resulting from cancer, AIDS, failed back surgery and certain nervous system disorders. The drug has restricted application as it must be administered by a doctor directly into the fluid surrounding the spinal cord.

Explore further: Scientists reveal new avenue for drug treatment in neuropathic pain

Related Stories

Scientists reveal new avenue for drug treatment in neuropathic pain

November 24, 2017
New research from King's College London has revealed a previously undiscovered mechanism of cellular communication, between neurons and immune cells, in neuropathic pain.

Separating side effects could hold key for safer opioids

November 16, 2017
Opioid pain relievers can be extremely effective in relieving pain, but can carry a high risk of addiction and ultimately overdose when breathing is suppressed and stops. Scientists have discovered a way to separate these ...

Integrative medicine approaches for pain treatment—can they be an alternative to opioids?

November 21, 2017
Can acupuncture and yoga help to fight the opioid epidemic? These and other integrative medicine approaches have shown at least preliminary evidence of effectiveness in pain management, according to an article in the December ...

Specialized compound could lead to chronic pain relief without the use of opioids

March 14, 2017
Purdue researchers have discovered a compound that could lead to the treatment of chronic pain without the need for patients to rely on opioids.

Recommended for you

Drug for spinal muscular atrophy prompts ethical dilemmas, bioethicists say

December 11, 2017
When the Food and Drug Administration approved the first drug for people with spinal muscular atrophy a year ago, clinicians finally had hope for improving the lives of patients with the rare debilitating muscular disease. ...

FDA's program to speed up drug approval shaved nearly a year off the process

December 7, 2017
Speeding the pace at which potentially lifesaving drugs are brought to market was a rallying cry for Donald Trump as a candidate, and is a stated priority of his Food and Drug Administration commissioner, Dr. Scott Gottlieb. ...

Dangers of commonly prescribed painkillers highlighted in study

December 6, 2017
Commonly prescribed painkillers need to be given for shorter periods of time to reduce the risk of obesity and sleep deprivation, a new study has revealed.

Viagra goes generic: Pfizer to launch own little white pill

December 6, 2017
The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales when the impotence pill gets its first ...

Surgery-related opioid doses can drop dramatically without affecting patients' pain

December 6, 2017
Some surgeons might be able to prescribe a third of opioid painkiller pills that they currently give patients, and not affect their level of post-surgery pain control, a new study suggests.

Four-fold jump in deaths in opioid-driven hospitalizations

December 4, 2017
People who end up in the hospital due to an opioid-related condition are four times more likely to die now than they were in 2000, according to research led by Harvard Medical School and published in the December issue of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.